ReviewCancer immunology, immunotherapy : CII2004
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning.
Review in Cancer immunology, immunotherapy : CII, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Review
- HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice.Scientific reports · 2021Article
- Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.Proteomics · 2011Article
- Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2010Article
- Article
- Novel approaches for identifying target antigens of autoreactive human B and T cells.Seminars in immunopathology · 2009Review
- Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.Cancer immunology, immunotherapy : CII · 2009Article
- Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.Cancer research · 2008Article
- Article
- Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.Journal of proteome research · 2008Article
- NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2007Article
- Identification of T-cell epitopes for cancer immunotherapy.Leukemia · 2007Review
- Immunotherapy of myeloid leukaemia.Cancer immunology, immunotherapy : CII · 2007Review
- Expression of the breast differentiation antigen NY-BR-1 in a phyllodes tumor of the vulva.Virchows Archiv : an international journal of pathology · 2007Article
- Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients.Cancer immunology, immunotherapy : CII · 2007Article
- An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.Journal of immunology (Baltimore, Md. : 1950) · 2006Article
- Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma.Cancer immunology, immunotherapy : CII · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of tumor infiltrating T cells has been shown to be associated with a favorable prognosis in different tumor types. Several strategies have been developed to identify relevant tumor antigens which can be used for active immunotherapy strategies. The SEREX technique (serological analysis of cDNA expression libraries) identifies tumor antigens based on a spontaneous humoral immune response in cancer patients. This technique is not limited to tumor types that can be grown in cell culture or depends on established T cell clones recognizing the autologous tumor. Several steps of analysis are mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy: expression analysis; serological analysis with sera from tumor patients and normal individuals; identification of potential peptide epitopes for CD8 T cells and evaluation in T cell assays. This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.